Revolution Medicines, Inc.
NASDAQ:RVMD · NASDAQ Global Select
+$3.60 today
Vol 4.01M · Avg 3.10M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:RVMD · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$1.4B of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-7.11, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 -100.0% | $11.6M -67.3% | $35.4M +20.4% | $29.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $16.6M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$16.6M | $0 -100.0% | $11.6M -67.3% | $35.4M +20.4% | $29.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $978.7M +65.3% | $592.2M +40.0% | $423.1M +67.2% | $253.1M +35.4% | $186.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $187.1M +92.3% | $97.3M +28.7% | $75.6M +86.3% | $40.6M +33.3% | $30.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.2B +69.1% | $689.5M +38.2% | $498.8M +69.8% | $293.7M +35.1% | $217.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $16.6M +40.0% | $11.8M +27.0% | $9.3M -3.6% | $9.7M +31.7% | $7.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$1.1B -85.1% | -$589.0M -36.9% | -$430.3M -79.7% | -$239.5M -33.2% | -$179.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | -3715.7% -3038.9pp | -676.8% -65.3pp | -611.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$1.2B -71.5% | -$689.5M -41.5% | -$487.2M -88.6% | -$258.3M -37.4% | -$188.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | -4207.1% -3477.1pp | -730.0% -90.3pp | -639.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $90.7M +4.4% | $86.9M +83.0% | $47.5M +418.7% | $9.2M +885.4% | $929.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $24.2M | $0 -100.0% | $303.0K | $0 -100.0% | $12.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $51.1M -42.4% | $88.7M +87.5% | $47.3M +416.6% | $9.2M +898.3% | $917.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$1.1B -88.3% | -$600.8M -36.6% | -$439.9M -76.6% | -$249.1M -33.2% | -$187.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | -3798.7% -3094.6pp | -704.1% -67.6pp | -636.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 +100.0% | -$753.0K +78.6% | -$3.5M -739.0% | -$420.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$1.1B -88.5% | -$600.1M -37.5% | -$436.4M -75.5% | -$248.7M -32.9% | -$187.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | -3768.3% -3065.3pp | -703.0% -66.4pp | -636.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$6 -66.2% | -$4 +7.3% | -$4 -25.3% | -$3 -24.7% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$6 -66.2% | -$4 +7.3% | -$4 -25.3% | -$3 -24.7% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $190.1M +13.3% | $167.7M +48.2% | $113.1M +40.3% | $80.6M +10.7% | $72.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $190.1M +13.3% | $167.7M +48.2% | $113.1M +40.3% | $80.6M +10.7% | $72.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Moderna, Inc.
NASDAQ:MRNA
$25.23B
Roivant Sciences Ltd.
NASDAQ:ROIV
$22.43B
Ascendis Pharma A/S
NASDAQ:ASND
$14.35B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.10B
Exelixis, Inc.
NASDAQ:EXEL
$13.03B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.28B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.63B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.73B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.59B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$217.07M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RVMD generate?
Revolution Medicines, Inc. (RVMD) reported $0.00 of revenue in fiscal 2025.
Is RVMD profitable?
Revolution Medicines, Inc. (RVMD) reported -$1,131,301,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.